Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 9/20 | 0.64 |
| ▸ | EGFR | P00533 | 4/20 | 0.49 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 2/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21542014 | 0.81 | CYP1A2 (0.55) | APPEGFRDHFRTLR8TLR7 | |
| SCHEMBL2256525 | 0.78 | APP (1.00) | APPEGFRNCF1POLBNR2F2 | |
| SCHEMBL21542020 | 0.74 | APP (0.57) | APPEGFRNCF1TLR8TLR7 | |
| SCHEMBL13975909 | 0.72 | CYP1A2 (0.60) | APPDHFRTLR8TLR7 | |
| SCHEMBL3110419 | 0.71 | CCNE1 (0.52) | APPEGFRNCF1POLBNR2F2 | |
| SCHEMBL3112153 | 0.71 | EGFR (0.54) | APPEGFRNCF1POLBNR2F2 | |
| SCHEMBL3113145 | 0.71 | APP (0.45) | APPEGFRNCF1POLBNR2F2 | |
| SCHEMBL3120767 | 0.71 | LMNA (0.46) | APPEGFRNCF1POLBNR2F2 | |
| SCHEMBL3115205 | 0.71 | CCNE2 (0.51) | APPEGFRPOLBNR2F2 | |
| SCHEMBL3116820 | 0.70 | APP (0.49) | APPEGFRNCF1POLBNR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518760-B2 | Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2022-12-06 | — | — | US | disclosed |
| US-20190345157-A1 | COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345157-A1 | COMPOUNDS | ABCB11, LTC4S, AQP1 | APP 2829/4885EGFR 4673/4885NCF1 423/4885 |
| US-11518760-B2 | Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds | P2RX5, PNPO, P2RX3 | APP 4242/4885EGFR 4282/4885NCF1 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.